7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 
      
    		                   
      cash flows from operating activities
    		                   
      net income
    		-16,288,000 -17,398,000 -15,922,000 -501,000 -15,360,000 -21,206,000 -18,676,000 -6,281,000 -17,521,000 -12,271,000 -13,454,000 -4,412,000 -12,133,000 -17,234,000 -9,036,000 -6,619,000 -6,418,000 -5,083,000 -2,432,000 
      adjustments to reconcile net income to net cash from operating activities
    		                   
      depreciation and amortization expense
    		2,778,000 2,576,000 2,461,000 2,237,000 2,157,000 2,116,000 1,909,000 1,769,000 1,564,000 1,095,000 924,000 917,000 459,000 423,000 334,000 276,000 189,000 103,000 117,000 
      benefit from allowance for credit losses
    		-69,000 81,000 500,000 566,000 174,000               
      share-based compensation expense
    		7,998,000 9,577,000 8,693,000 8,555,000 7,900,000 6,740,000 7,408,000 5,872,000 5,192,000 3,596,000 2,692,000 2,470,000 2,269,000 1,963,000 1,409,000 1,293,000 839,000 875,000 402,000 
      non-cash lease expense
    		556,000 555,000 578,000 1,742,000 -575,000 590,000 592,000 593,000 604,000 638,000 626,000 512,000 845,000 829,000 336,000     
      amortization of debt issuance costs
    		75,000 74,000 74,000 75,000 74,000 74,000 75,000 74,000 75,000 74,000 74,000 75,000 74,000 50,000 45,000 43,000 45,000 45,000 43,000 
      amortization (accretion) of premium (discount) on marketable securities
    		-5,000 -37,000 -77,000                 
      other
    		531,000 32,000 187,000 358,000 21,000 69,000 90,000 41,000 159,000 -20,000 25,000 0        
      net changes in operating assets and liabilities, net of acquisitions
    		                   
      accounts receivable
    		-2,557,000 696,000 9,289,000 -17,192,000 1,208,000 2,476,000 7,821,000 -13,422,000 2,235,000 -1,907,000 3,793,000 -11,097,000 -2,054,000 -430,000 2,542,000 -6,973,000 -1,764,000 742,000 3,769,000 
      inventory
    		973,000 -4,457,000 1,315,000 4,356,000 -2,332,000 -5,419,000 -6,615,000 67,000 -3,211,000 -3,515,000 -3,189,000 -2,742,000 -3,617,000 -1,862,000 -548,000 -378,000 -2,799,000 -389,000 478,000 
      prepaid expenses and other assets
    		-615,000 -1,285,000 1,369,000 1,348,000 653,000 1,680,000 -1,495,000 -182,000 613,000 -678,000 -963,000 390,000 -19,000 -2,272,000 1,233,000 751,000 -249,000 -2,540,000 -379,000 
      other non-current assets
    		62,000 -289,000 -76,000 -18,000       -69,000 0 -12,000 0 -134,000     
      operating lease liabilities
    		-829,000 -768,000 -785,000 -2,326,000 1,144,000 -634,000 -657,000    -478,000 -36,000 720,000 2,525,000 -133,000     
      accounts payable
    		-3,856,000 6,736,000 2,701,000 -8,127,000 576,000 -3,076,000 9,314,000 3,155,000 534,000 3,070,000 -3,592,000 787,000 4,782,000 -350,000 -607,000 1,614,000 -479,000 1,829,000 -1,173,000 
      accrued liabilities
    		2,118,000 857,000 -6,166,000 4,850,000 -6,810,000 975,000 -6,918,000 9,482,000 1,183,000 939,000 -4,076,000 6,903,000 1,180,000 1,661,000 -2,619,000 5,873,000 1,337,000 567,000 -1,167,000 
      net cash from operating activities
    		-9,092,000 -3,050,000 4,198,000 -4,207,000 -11,842,000 -13,897,000 -7,221,000 532,000 -9,513,000 -8,335,000 -17,259,000 -5,358,000 -7,483,000 -10,566,000 -7,241,000 -3,752,000 -9,264,000 -3,731,000 -446,000 
      capex
    		-2,809,000 -4,767,000 -3,543,000 -3,074,000 -2,863,000 -1,729,000 -3,927,000 -2,248,000 -3,501,000 -4,231,000 -1,478,000 -2,332,000 -5,857,000 -5,168,000 -1,481,000 -900,000 -939,000 -670,000 -196,000 
      free cash flows
    		-11,901,000 -7,817,000 655,000 -7,281,000 -14,705,000 -15,626,000 -11,148,000 -1,716,000 -13,014,000 -12,566,000 -18,737,000 -7,690,000 -13,340,000 -15,734,000 -8,722,000 -4,652,000 -10,203,000 -4,401,000 -642,000 
      cash flows from investing activities
    		                   
      purchases of available-for-sale marketable securities
    		-4,640,000 -15,159,000 -15,090,000 -18,689,000 -24,179,000 0 -28,711,000 -29,790,000 -19,118,000 -21,407,000 -99,550,000         
      sales and maturities of available-for-sale marketable securities
    		16,185,000 16,669,000 16,739,000 25,184,000 32,805,000 24,162,000 36,396,000 37,045,000 27,216,000           
      purchases of property and equipment
    		-2,809,000 -4,767,000 -3,543,000 -3,074,000 -2,863,000 -1,729,000 -3,927,000 -2,248,000 -3,501,000 -4,231,000 -1,478,000 -2,332,000 -5,857,000 -5,168,000 -1,481,000 -900,000 -939,000 -670,000 -196,000 
      net cash from investing activities
    		8,736,000 -3,257,000 -1,894,000 3,421,000 5,763,000 22,433,000 3,758,000 5,007,000 4,597,000 -10,423,000 -80,480,000 -64,012,000 -5,857,000 -5,168,000 -1,481,000 -900,000 -939,000 -670,000 -196,000 
      cash flows from financing activities
    		                   
      proceeds from insurance premium financing
    		570,000                   
      payments on insurance premium financing
    		-409,000                   
      proceeds from exercise of employee stock options
    		241,000 116,000 119,000 57,000 8,000 311,000 52,000 178,000 159,000 1,180,000 352,000 297,000 353,000 165,000 1,372,000 1,026,000 41,000 194,000 569,000 
      taxes from withheld shares
    		-412,000 -14,000 -401,000 -31,000 0 0 -237,000             
      net cash from financing activities
    		-10,000 987,000 -282,000 26,000 8,000 311,000 -185,000 165,000 159,000 1,180,000 107,879,000 297,000 353,000 18,784,000 1,372,000 1,026,000 41,000 107,804,000 -1,219,000 
      net increase in cash and cash equivalents
    		-366,000 -5,320,000 2,022,000 -760,000 -6,071,000 8,847,000 -3,648,000    10,140,000 -69,073,000 -12,987,000   -3,626,000 -10,162,000   
      cash and cash equivalents at beginning of period
    		0 0 11,350,000 0 0 0 12,982,000 0 0 0 19,473,000 0 0 0 105,833,000 0 0 0 18,079,000 
      cash and cash equivalents at end of period
    		-366,000 -5,320,000 13,372,000 -760,000 -6,071,000 8,847,000 9,334,000 5,704,000 -4,757,000 -17,578,000 29,613,000 -69,073,000 -12,987,000 3,050,000 98,483,000 -3,626,000 -10,162,000 103,403,000 16,218,000 
      supplemental disclosure of cash flow information
    		                   
      cash paid for interest
    		1,259,000 1,266,000 1,229,000 1,223,000 1,242,000 1,173,000 1,317,000 1,304,000 1,296,000 1,282,000 1,285,000 1,311,000 1,190,000 946,000 951,000 983,000 0 972,000 1,945,000 
      operating lease right-of-use asset and lease liability adjustment due to lease incentive
    		   -80,000 2,000   0 -9,000 22,000 -35,000         
      noncash investing activities
    		                   
      unrealized (gains) losses, net on marketable securities
    		-33,000 7,000 40,000 94,000 -217,000 95,000 94,000             
      noncash financing activities
    		                   
      legal cost financing
    		524,000 183,000 45,000                 
      unsettled matured marketable security and receivable from broker
    		     -100,000 2,100,000 -3,000,000            
      gain on fair value adjustment to derivative liability
    		           0 0 -83,000 -90,000 0    
      debt extinguishment loss
    		           0 0       
      loss on impairment of long-lived assets
    		                   
      acquisition, net of cash acquired
    		       0 0           
      proceeds from interest bearing term debt
    		           0 0       
      proceeds from interest bearing revolving debt
    		           0 0       
      debt issuance costs
    		                   
      payments on interest bearing debt
    		                   
      proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of 7.5 million
    		        0 0 107,527,000         
      operating lease right-of-use assets obtained in exchange for new lease liabilities
    		           0 0 0 15,300,000     
      noncash portion of internally developed software
    		                   
      accretion (amortization) of discount (premium) on marketable securities
    		    -233,000 -350,000 -335,000 -375,000 -368,000 -366,000 -297,000         
      unsettled marketable security purchase and payable to broker
    		                   
      benefit from allowance for doubtful accounts
    		      159,000    38,000         
      recovery of loss reserve for surgical instruments
    		          -23,000         
      payable to broker for unsettled marketable security purchases
    		          710,000         
      proceeds from issuance of common stock from public offering, net of issuance costs and underwriting discount of 7.5 million and 10.6 million
    		                   
      net changes in operating assets and liabilities, net of acquisitions:
    		                   
      other liabilities
    		       -616,000 -575,000           
      payments on ppp loan
    		                   
      net decrease in cash and cash equivalents
    		       5,704,000 -4,757,000      -7,350,000    -1,861,000 
      supplemental disclosure of cash flow information:
    		                   
      noncash investing activities:
    		                   
      unrealized (gains) losses on marketable securities
    		                   
      noncash financing activities:
    		                   
      issuance of common stock upon exercise of warrants
    		               0 0   
      conversion of convertible preferred stock and accrued dividends on convertible preferred stock into common stock
    		               0 0   
      (recovery) benefit from allowance for doubtful accounts
    		        1,000        16,000 5,000 -77,000 
      recovery of inventory obsolescence
    		              -3,000     
      repayment of term loan
    		            0       
      unrealized losses on marketable securities
    		        -71,000 163,000 29,000         
      net changes in operating assets and liabilities:
    		                   
      maturities of available-for-sale marketable securities
    		          20,548,000         
      impairment of capitalized surgical instruments
    		                   
      proceeds from ppp loan
    		                   
      proceeds from issuance of common stock upon initial public offering, net of issuance costs and underwriting fees of 10.6 million
    		               0 0   
      initial fair value of derivative liability
    		                   
      recovery for allowance for doubtful accounts
    		                   
      (recovery of) benefit from inventory obsolescence
    		                   
      repayment of ppp loan
    		                   
      debt issuance costs paid to third parties
    		            0       
      supplemental disclosure of noncash financing activities:
    		                   
      (recovery) for allowance for doubtful accounts
    		                   
      (recovery) provision of inventory obsolescence
    		                   
      supplemental disclosure of noncash investing activities:
    		                   
      property and equipment received in exchange for lease liability
    		                   
      provision (recovery) for allowance for doubtful accounts
    		              30,000     
      unpaid offering costs included in accounts payable and accrued liabilities
    		                  1,118,000 
      benefit from inventory obsolescence
    		               168,000 91,000   
      loss on early settlement of debt
    		                   
      proceeds from interest bearing debt
    		                   
      repayments on ppp loan
    		                   
      issuance of warrants for class a common stock in connection with the company’s credit facility
    		                   
      proceeds from sba loan
    		                   
      repayments on sba loan
    		                0   
      (recovery) benefit from inventory obsolescence
    		                  -27,000 
      repayment on sba loan
    		                  -1,788,000 
      non-cash financing activities:
    		                   
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.